Holen Sie sich die Stockscreener-App
4.26
1.43%
0.06
Vorhandelsmarkt:
4.36
0.10
+2.35%
Enlivex Ltd Aktie (ENLV) Neueste Nachrichten
ENLV|Enlivex Therapeutics Ltd|Price:4.250|Chg%:+0.050 - TradingKey
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Market Sentiment - Benzinga España
Enlivex Therapeutics Ltd (ENLV) Balance Sheet - TradingKey
Enlivex Therapeutics Ltd (ENLV) Cash Flow - TradingKey
Enlivex Therapeutics Ltd (ENLV) Income Statement - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Institutional Confidence - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enlivex(ENLV) Stock Options Chain | Quotes & News - Moomoo
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enlivex Ltd (1BT.DU) latest press releases and corporate news - Yahoo Finance UK
ENLV|Enlivex Therapeutics Ltd|Price:4.200|Chg%:-0.160 - TradingKey
Enlivex Ltd (1BT.DU) stock price, news, quote and history - Yahoo Finance UK
Enlivex Ltd. (ENLV) Posts Modest Gains as Shares Consolidate Near SupportRisk Reward Setups - dars.gov.et
Enlivex Reveals $1.1 Billion RAIN Token Treasury and $66.16 NAV Per Share - The Globe and Mail
Enlivex Ltd. (ENLV) Rallies 1.71% – Testing Key Resistance at $5.0RVOL Spike - dars.gov.et
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion - The Manila Times
Enlivex (Nasdaq: ENLV) details $1.1B RAIN token holdings and NAV - Stock Titan
Enlivex’s Net Asset Value Per Share Was $66.16 on July 18 - Stock Titan
Enlivex Ltd. (ENLV) upgraded to buy: Here's why - MSN
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment - GuruFocus
Enlivex Wins FDA RMAT Status for Allocetra in Age-Related Knee Osteoarthritis - TipRanks
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why - Yahoo Finance
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
FDA grants regenerative medicine designation to Enlivex therapy By Investing.com - Investing.com South Africa
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis - The Manila Times
FDA grants regenerative medicine designation to Enlivex therapy - Investing.com
Enlivex (ENLV) wins FDA RMAT designation for Allocetra in age-related knee osteoarthritis - Stock Titan
FDA flags Enlivex’s Allocetra as potential new option for painful knee osteoarthritis - Stock Titan
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA - Investing.com Canada
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023. - marketscreener.com
Enlivex: Performance & Quotes, ENLV Stock Price on Nasdaq Exchange - marketscreener.com
Enlivex: Dividend historical data and projections - marketscreener.com
Enlivex: Shareholders Board Members Managers and Company Profile | IL0011319527 - marketscreener.com
Enlivex Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity - 富途牛牛
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026 - marketscreener.com
ENLV Q4 2025 Earnings: Massive EPS Miss and Continued Cash Burn PressureFinal Results - DonanımHaber
Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut - The Globe and Mail
Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com - Investing.com Nigeria
Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech - Ad Hoc News
Enlivex (ENLV) Implements Reverse Stock Split - GuruFocus
Enlivex announces 1-for-15 reverse stock split effective Wednesday - Investing.com
Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count - Stock Titan
Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues - Stock Titan
Enlivex announces 1-for-15 reverse stock split effective July 9, 2026, adjusting shares and par value. - Pluang
ENLV Q4 2025 Earnings: Staggering EPS Miss as Company Reports Significant LossesMargin Improvement Report - dars.gov.et
ENLV Q4 2025 Earnings: EPS Misses Estimates by Wide Margin Amid No RevenueReturn On Equity - dars.gov.et
Discontinued operations of Enlivex Ltd. – DUS:1BT - TradingView
Preferred dividends of Enlivex Ltd. – DUS:1BT - TradingView
Enterprise value to revenue forward of Enlivex Ltd. – DUS:1BT - TradingView
Price to sales forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Price to book forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBIT forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBITDA forward of Enlivex Ltd. – DUS:1BT - TradingView
Enlivex Ltd. Earnings and Revenue – DUS:1BT - TradingView
Enlivex Ltd. Actuals & Estimates (NASDAQ:ENLV) - TradingView
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):